Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $569.00 | 11 | 97.4% |
| Education | $15.00 | 1 | 2.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $446.80 | 10 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $122.20 | 1 | $0 (2018) |
| Sandoz Inc. | $15.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $90.63 | 1 | Celgene Corporation ($90.63) |
| 2018 | $280.26 | 8 | Celgene Corporation ($158.06) |
| 2017 | $213.11 | 3 | Celgene Corporation ($198.11) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/25/2019 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $90.63 | General |
| Category: Dermatology | ||||||
| 11/29/2018 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $100.05 | General |
| Category: Dermatology | ||||||
| 09/17/2018 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $6.59 | General |
| 08/28/2018 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $9.69 | General |
| 07/18/2018 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $4.28 | General |
| 05/23/2018 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $4.85 | General |
| 05/08/2018 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $19.70 | General |
| 04/24/2018 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $12.90 | General |
| 03/08/2018 | Regeneron Healthcare Solutions, Inc. | DUPIXENT DUPILUMAB INJECTION (Biological) | Food and Beverage | In-kind items and services | $122.20 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/13/2017 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $73.09 | General |
| Category: Dermatology | ||||||
| 06/22/2017 | Sandoz Inc. | KERYDIN (Drug) | Education | In-kind items and services | $15.00 | General |
| Category: DERMATOLOGY | ||||||
| 04/05/2017 | Celgene Corporation | Otezla (Drug) | Food and Beverage | In-kind items and services | $125.02 | General |
| Category: Dermatology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,717 | 2,750 | $481,437 | $142,296 |
| 2022 | 17 | 1,336 | 2,136 | $357,750 | $107,724 |
| 2021 | 18 | 1,689 | 2,709 | $474,337 | $149,554 |
| 2020 | 18 | 1,371 | 2,029 | $343,364 | $99,880 |
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 308 | 415 | $111,220 | $37,998 | 34.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 252 | 289 | $52,598 | $17,669 | 33.6% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 156 | 184 | $45,080 | $13,380 | 29.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 228 | 291 | $53,544 | $11,129 | 20.8% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2023 | 106 | 138 | $40,020 | $10,975 | 27.4% |
| 11311 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.6-1.0 cm | Office | 2023 | 50 | 53 | $17,755 | $5,336 | 30.1% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 36 | 42 | $22,764 | $5,263 | 23.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 40 | 40 | $16,600 | $5,007 | 30.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 163 | 876 | $14,892 | $4,657 | 31.3% |
| 11302 | Shaving of skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 41 | 42 | $14,700 | $4,477 | 30.5% |
| 11310 | Shaving of skin growth of face, ears, eyelids, nose, lips, or mouth, 0.5 cm or less | Office | 2023 | 45 | 53 | $14,045 | $3,994 | 28.4% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 63 | 69 | $17,181 | $3,686 | 21.5% |
| 10060 | Simple or single drainage of skin abscess | Office | 2023 | 35 | 38 | $9,675 | $3,547 | 36.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 47 | 47 | $12,784 | $3,367 | 26.3% |
| 11300 | Shaving of skin growth of body, arms, or legs, 0.5 cm or less | Office | 2023 | 51 | 58 | $11,136 | $3,209 | 28.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 21 | $7,560 | $2,815 | 37.2% |
| 11306 | Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.6-1.0 cm | Office | 2023 | 30 | 33 | $9,735 | $2,773 | 28.5% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 14 | 15 | $5,955 | $1,930 | 32.4% |
| 11305 | Shaving of skin growth of scalp, neck, hands, feet, or genitals, 0.5 cm or less | Office | 2023 | 18 | 19 | $4,085 | $1,060 | 25.9% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 17 | 27 | $108.00 | $23.19 | 21.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 263 | 346 | $92,728 | $30,864 | 33.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 223 | 242 | $44,044 | $14,998 | 34.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 144 | 162 | $39,585 | $12,239 | 30.9% |
| 11301 | Shaving of skin growth of body, arms, or legs, 0.6-1.0 cm | Office | 2022 | 95 | 124 | $35,960 | $10,557 | 29.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 183 | 235 | $43,240 | $8,537 | 19.7% |
About Dr. Tara Whelan, DO
Dr. Tara Whelan, DO is a Dermatology healthcare provider based in Westerly, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/02/2011. The National Provider Identifier (NPI) number assigned to this provider is 1619273042.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tara Whelan, DO has received a total of $584.00 in payments from pharmaceutical and medical device companies, with $90.63 received in 2019. These payments were reported across 12 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($569.00).
As a Medicare-enrolled provider, Whelan has provided services to 6,113 Medicare beneficiaries, totaling 9,624 services with total Medicare billing of $499,454. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Westerly, RI
- Active Since 02/02/2011
- Last Updated 11/28/2012
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1619273042
Products in Payments
- Otezla (Drug) $388.79
- DUPIXENT DUPILUMAB INJECTION (Biological) $122.20
- KERYDIN (Drug) $15.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.